Oncology PracticeStudy supports need for less toxic therapies in FLJanuary 16, 2019Follicular LymphomaIndolent Lymphoma
The Journal of Community and Supportive OncologyEmerging biosimilars market presents opportunities and challengesDecember 6, 2018Patient & Survivor CareFollicular Lymphoma
Oncology PracticePhase 3 study confirms biosimilarity of PF-05280586 with rituximabDecember 5, 2018Lymphoma & Plasma Cell DisordersAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology TimesFDA approves biosimilar rituximab for NHLNovember 29, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsFDA approves rituximab biosimilar for lymphomaNovember 28, 2018Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsCortactin expression aids in CLL-MCL differentialNovember 28, 2018CLLMantle Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesBiosimilar deemed equivalent to rituximab in FLNovember 21, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesElderly NHL patients have higher NRM after HSCTNovember 20, 2018Lymphoma & Plasma Cell DisordersTransplantationNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsRituximab biosimilar looks equivalent in follicular lymphomaNovember 19, 2018Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesR-CHOP effective as first-line treatment in FLNovember 16, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsR-CHOP looks viable as first line in follicular lymphomaNovember 15, 2018Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular LymphomaB Cell Lymphoma
Hematology TimesCombo appears safe, active in rel/ref NHLNovember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology TimesSandoz won’t seek U.S. approval for rituximab biosimilarNovember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsSandoz halts pursuit of U.S. approval for rituximab biosimilarNovember 5, 2018CLLLymphoma & Plasma Cell DisordersIndolent LymphomaFollicular LymphomaB Cell Lymphoma
Hematology NewsCheckpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular LymphomaB Cell Lymphoma
